A breakthrough publication shows the SneakPeek Early Gender DNA Test predicted fetal sex accurately for 115 of 115 women recruited from 12 independent clinics across the US.
LA JOLLA, Calif., July 19, 2022 /PRNewswire-PRWeb/ -- Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces a new peer-reviewed publication titled, "SneakPeek Early Gender Test: The Earliest and Most Accurate Method for Fetal Sex Determination at 6-Weeks' Gestation" in the Clinics in Mother and Child Health journal.
In the study, 115 women had DNA blood samples taken at 6, 7, and 8-10 weeks gestational age independently at 12 clinics in the US between May and September 2021. The samples were sent to SneakPeek labs and run through the SneakPeek test process at each of the three time points. For all 115 women, the gender results matched at every timepoint. For 103 of the women, the gender results were further confirmed through sonography.
SneakPeek is the only public or private entity to publish accurate fetal sex results at 6 weeks into pregnancy. No prior study has shown gender identification with high accuracy from maternal plasma earlier than 7 weeks of gestation.
"We're proud to be engaging in cutting-edge research," says Gateway Genomics CEO, Chris Jacob. "We're the only group in the world, including academic universities as well as companies, to develop a test that is sensitive enough to detect male chromosomes from maternal blood this early in pregnancy, when the fetal-cell fraction in mom's blood is extremely low, and every day makes a significant difference. The team has made a monumental scientific accomplishment here."
The SneakPeek Early Gender DNA test has been available to moms to find out the sex of their babies since 2014, when the test was offered at 9 weeks into pregnancy. Over the years, the Gateway Genomics team honed the sensitivity of the test, reducing the timeline from 9 to 8 to 7 weeks into pregnancy, always maintaining an accuracy rate of over 99%.
"While SneakPeek isn't the only at-home fetal sex test on the market, we pride ourselves in being far-and-away the market leader, not only in families served, but also in scientific integrity," continues Mr. Jacob. "Other companies claim to detect fetal sex at 7 or 8 weeks but haven't submitted their data to be published in peer-reviewed journals. To us, this feels like a black box. We believe any commercial lab test offered to customers should undergo rigorous review by the scientific community to be credible. This paper in the Clinics in Mother and Child Health journal is the 9th one that's been published on SneakPeek technology. Because we're delivering a life-changing piece of information to families, we hold ourselves to the highest scientific standards to ensure parents can trust and depend on the results we provide them."
In 2021, Gateway Genomics ranked #601 in the Inc. 5000 list of fastest-growing private companies in the U.S., #22 in the Health sector. In 2021's Inc. 5000 California list, the company was ranked the 56th fastest-growing private company in the state, and #6 in the Health sector. Gateway Genomics' flagship product, SneakPeek Gender, is an easy-to-use DNA test that lets parents know the fetal sex of their babies as early as 6 weeks into pregnancy, with 99.9% accuracy.
About Gateway Genomics
Gateway Genomics is a personal genomics company with the mission to develop accurate, innovative, prenatal and pediatric tests that give families insight into the health and development of their children. Since inception, more than 500,000 SneakPeek DNA tests have been provided to help new parents bond with and learn about their babies, make plans, and connect with friends and family around them. Gateway Genomics is located in La Jolla, CA.
Media Contact
Angela Shue, Gateway Genomics, 8582554330, [email protected]
SOURCE Gateway Genomics
Share this article